New! Sign up for our free email newsletter.
Science News
from research organizations

Highly accurate blood test diagnoses Alzheimer's disease, measures extent of dementia

Could help determine which patients are likely to benefit from new Alzheimer's drugs

Date:
March 31, 2025
Source:
WashU Medicine
Summary:
A newly developed blood test for Alzheimer's disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a new study.
Share:
FULL STORY

A newly developed blood test for Alzheimer's disease not only aids in the diagnosis of the neurodegenerative condition but also indicates how far it has progressed, according to a study by researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden.

Several blood tests for Alzheimer's disease are already clinically available, including two based on technology licensed from WashU. Such tests help doctors diagnose the disease in people with cognitive symptoms, but do not indicate the clinical stage of the disease symptoms -- that is, the degree of impairment in thinking or memory due to Alzheimer's dementia. Current Alzheimer's therapies are most effective in early stages of the disease, so having a relatively easy and reliable way to gauge how far the disease has progressed could help doctors determine which patients are likely to benefit from drug treatment and to what extent. The new test can also provide insight on whether a person's symptoms are likely due to Alzheimer's versus some other cause.

The study is published March 31 in Nature Medicine.

In the study, the researchers found that levels of a protein called MTBR-tau243 in the blood accurately reflect the amount of toxic accumulation of tau aggregates in the brain and correlate with the severity of Alzheimer's disease. Analyzing blood levels of MTBR-tau243 from a group of people with cognitive decline, the researchers were able to distinguish between people with early- or later-stage Alzheimer's disease and separate both groups of Alzheimer's patients from people whose symptoms were caused by something other than Alzheimer's disease.

"This blood test clearly identifies Alzheimer's tau tangles, which is our best biomarker measure of Alzheimer's symptoms and dementia," said co-senior author Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. "In clinical practice right now, we don't have easy or accessible measures of Alzheimer's tangles and dementia, and so a tangle blood test like this can provide a much better indication if the symptoms are due to Alzheimer's and may also help doctors decide which treatments are best for their patients."

Tracking Alzheimer's disease progression from blood

Alzheimer's disease involves a build-up of a protein, called amyloid, into plaques in the brain, followed by the development of tangles of tau protein years later. Cognitive symptoms emerge around the time tau tangles become detectable, and symptoms worsen as the tangles spread. The gold standard for staging Alzheimer's disease is positron emission tomography (PET) brain scans for amyloid plaques and tau tangles. Amyloid scans yield information about the presymptomatic and early symptomatic stages, while tau scans are useful for tracking later stages of the disease. PET brain scans are highly accurate but expensive, time-consuming and frequently unavailable outside of major research centers, so they are not widely used.

Bateman leads a team that is developing blood tests for Alzheimer's disease as a more accessible alternative to brain scans. They have developed two blood tests that correlate closely with the amount of amyloid plaques in the brain. Both are now used by doctors to aid diagnosis. But until now, there has been no blood test that reports on tau levels in the brain.

In a previous study, Bateman and colleagues -- including co-first authors Kanta Horie, PhD, a research associate professor of neurology at WashU Medicine, and Gemma Salvadó, PhD, then a postdoctoral researcher at Lund University, and co-senior author Oskar Hansson, MD, PhD, a professor of neurology at Lund University -- showed that cerebrospinal fluid levels of MTBR-tau243 correlate closely with tau tangles in the brain. In the current study, the team extended the analysis to blood. A blood sample is easier to collect than cerebrospinal fluid, which is obtained via spinal tap.

The researchers developed a technique to measure MTBR-tau243 levels in people's blood and compared it to the amount of tau tangles in their brains as measured by brain scans. They piloted the approach on data from two cohorts: volunteers at WashU Medicine's Charles F. and Joanne Knight Alzheimer Disease Research Center, which included 108 people, and a subset of 55 people from the Swedish BioFINDER-2 cohort. To assess whether the approach was generalizable, they validated it in an independent dataset consisting of the remaining 739 people in the BioFINDER-2 cohort.

The people in the two cohorts represented all but the most severe end of the spectrum of Alzheimer's disease, from the presymptomatic stage when brain amyloid levels are elevated but people remain cognitively healthy, through early-stage disease with mild cognitive impairments, to late symptomatic disease when patients exhibit full-blown dementia. For comparison, cognitively healthy people with normal amyloid levels, and people with cognitive symptoms due to conditions other than Alzheimer's disease, were included.

The researchers' analysis showed that blood MTBR-tau243 levels reflected the amount of tau tangles in the brain with 92% accuracy. MTBR-tau243 levels in the blood were normal in asymptomatic people regardless of amyloid status, meaning that blood MTBR-tau243 levels do not change between healthy people and people in the presymptomatic stage of Alzheimer's disease with amyloid plaques.

Among people with cognitive symptoms due to Alzheimer's disease, MTBR-tau243 levels were significantly elevated for people in the mild cognitive impairment phase of Alzheimer's disease and much higher -- up to 200 times -- for those in the dementia phase. Those differences translated into clear separation of people in early- and late-stage Alzheimer's disease. At the same time, MTBR-tau243 levels were normal in people with cognitive symptoms due to diseases other than Alzheimer's, meaning that the test effectively distinguished Alzheimer's dementia from other kinds of dementia.

The technology underlying the blood test for tau aggregates has been licensed by WashU to C2N Diagnostics, a WashU startup that developed the blood tests for amyloid. These amyloid tests incorporate measures of another form of tau called p-tau217.

"I believe we will use blood-based p-tau217 to determine whether an individual has Alzheimer's disease, but MTBR-tau243 will be a highly valuable complement in both clinical settings and research trials," said Hansson. "When both of these biomarkers are positive, the likelihood that Alzheimer's is the underlying cause of a person's cognitive symptoms increases significantly, compared to when only p-tau217 is abnormal. This distinction is crucial for selecting the most appropriate treatment for each patient."

Blood tests could inform personalized Alzheimer's treatment

Two Alzheimer's therapies have been approved by the Food and Drug Administration (FDA) to slow progression of the disease, and both work by lowering amyloid levels in the brain. Horie said the number and variety of available Alzheimer's medications may soon be expanding, as several experimental drugs that target tau or other aspects of Alzheimer's disease are in the pipeline. With blood tests to diagnose and stage the disease, doctors would be able to tailor treatments to the patient's particular disease state.

"We're about to enter the era of personalized medicine for Alzheimer's disease," Horie said. "For early stages with low tau tangles, anti-amyloid therapies could be more efficacious than in late stages. But after the onset of dementia with high tau tangles, anti-tau therapy or one of the many other experimental approaches may be more effective. Once we have a clinically available blood test for staging, plus treatments that work at different stages of the disease, doctors will be able to optimize their treatment plans for the specific needs of each patient."


Story Source:

Materials provided by WashU Medicine. Original written by Tamara Schneider. Note: Content may be edited for style and length.


Journal Reference:

  1. Kanta Horie, Gemma Salvadó, Rama K. Koppisetti, Shorena Janelidze, Nicolas R. Barthélemy, Yingxin He, Chihiro Sato, Brian A. Gordon, Hong Jiang, Tammie L. S. Benzinger, Erik Stomrud, David M. Holtzman, Niklas Mattsson-Carlgren, John C. Morris, Sebastian Palmqvist, Rik Ossenkoppele, Suzanne E. Schindler, Oskar Hansson, Randall J. Bateman. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nature Medicine, 2025; DOI: 10.1038/s41591-025-03617-7

Cite This Page:

WashU Medicine. "Highly accurate blood test diagnoses Alzheimer's disease, measures extent of dementia." ScienceDaily. ScienceDaily, 31 March 2025. <www.sciencedaily.com/releases/2025/03/250331122226.htm>.
WashU Medicine. (2025, March 31). Highly accurate blood test diagnoses Alzheimer's disease, measures extent of dementia. ScienceDaily. Retrieved April 1, 2025 from www.sciencedaily.com/releases/2025/03/250331122226.htm
WashU Medicine. "Highly accurate blood test diagnoses Alzheimer's disease, measures extent of dementia." ScienceDaily. www.sciencedaily.com/releases/2025/03/250331122226.htm (accessed April 1, 2025).

Explore More

from ScienceDaily

RELATED STORIES